Sun Pharma's generic Cymbalta gets tentative approval from FDA

11/28/2010 | Business Standard (India)

The FDA has issued tentative marketing approval for Sun Pharmaceutical Industries' duloxetine hydrochloride, a copy of Eli Lilly and Co.'s Cymbalta. The drug is used for treating generalized anxiety disorder, diabetic peripheral neuropathic pain and major depressive disorder. Sun will launch the generic product in 20-, 30- and 60-milligram capsules.

View Full Article in:

Business Standard (India)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR
Clinical Appeals RN
MJHS
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ